Follow Us:
Etoricoxib

Arcoxia

Etoricoxib

Etoricoxib is a nonsteroidal anti-inflammatory drug (NSAID) used to relieve pain and inflammation associated with osteoarthritis, rheumatoid arthritis, ankylosing spondylitis, and acute gout. It belongs to the class of selective cyclooxygenase-2 (COX-2) inhibitors. Etoricoxib works by inhibiting the COX-2 enzyme, reducing prostaglandin production and thereby decreasing pain, swelling, and inflammation. It is administered orally according to the prescribed dosage. Common side effects include headache, dizziness, indigestion, and swelling of the legs. Serious adverse effects may include increased blood pressure, kidney problems, and cardiovascular events; therefore, blood pressure and kidney function should be monitored during treatment.

Dosage Form:
Dosage Strength:
CAS No.: 202409-33-4
Status:
Manufacturer:
Group: Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
Sub Group: Selective COX-2 Inhibitors

Uses of Etoricoxib

Etoricoxib was historically used as a respiratory medicine for the symptomatic management of certain respiratory conditions. Its former uses included:

  • Osteoarthritis: Relief of joint pain, stiffness and inflammation associated with degenerative joint disease.
  • Rheumatoid Arthritis: Management of pain and inflammation associated with chronic inflammatory arthritis.
  • Ankylosing Spondylitis: Reduction of pain, stiffness and inflammation affecting the spine and joints.
  • Acute Gout: Relief of pain and inflammation during acute gout attacks with selected medicines.
  • Acute Pain: Short-term treatment of moderate to severe pain, depending on the formulation and approved indication.
  • Postoperative Pain: Parecoxib may be used for short-term management of postoperative pain in appropriate clinical settings.
  • Dysmenorrhea: Relief of menstrual pain with selected medicines such as celecoxib.

Contraindication of Etoricoxib

Etoricoxib was historically subject to specific precautions during administration to ensure patient safety. Its former precautions included:

  • Known hypersensitivity to the active ingredient or previous serious allergic reactions to NSAIDs.
  • History of serious allergic reactions, including asthma, urticaria or angioedema following aspirin or other NSAIDs.
  • Active peptic ulceration or gastrointestinal bleeding.
  • Severe heart failure or certain established cardiovascular conditions.
  • Severe renal or hepatic impairment, where specified for the individual medicine.
  • Active gastrointestinal bleeding or significant bleeding disorders.
  • Perioperative pain management associated with coronary artery bypass graft (CABG) surgery.
  • Pregnancy during the third trimester.
  • Previous serious skin reactions associated with the medicine.

Precautions for Etoricoxib

Etoricoxib was majorly subjected to specific precautions during administration to ensure patient safety. Its former precautions included:

  • Cardiovascular Health: Patients with hypertension, coronary artery disease, previous stroke or other cardiovascular risk factors require careful assessment because selective COX-2 inhibitors may increase the risk of heart attack and stroke.
  • Gastrointestinal Health: Although gastrointestinal risks may be lower than with non-selective NSAIDs, ulcers, bleeding and perforation can still occur.
  • Kidney Function: Caution is necessary in patients with renal impairment, dehydration or conditions affecting kidney function.
  • Blood Pressure: These medicines may cause fluid retention, swelling and increased blood pressure.
  • Liver Function: Liver enzymes may require monitoring, particularly in patients with pre-existing hepatic conditions.
  • Pregnancy: NSAIDs should generally be avoided from 20 weeks of pregnancy unless specifically advised by a healthcare professional and avoided from 30 weeks because of fetal risks.
  • Elderly Patients: Older adults may have a greater risk of cardiovascular, renal and gastrointestinal complications.
  • Treatment Duration: Use the lowest effective dose for the shortest appropriate duration.

Drug Interactions for Etoricoxib

Potential drug interactions were historically documented when Etoricoxib was prescribed alongside certain medications. These included:

  • Anticoagulants: Warfarin and direct oral anticoagulants may increase bleeding risk. INR monitoring may be required with warfarin.
  • Antiplatelet Drugs: Aspirin and clopidogrel may increase gastrointestinal bleeding risk.
  • Corticosteroids: Prednisolone and other corticosteroids may increase the risk of gastrointestinal ulcers and bleeding.
  • Other NSAIDs: Combining selective COX-2 inhibitors with non-selective NSAIDs may increase gastrointestinal, cardiovascular and renal adverse effects.
  • ACE Inhibitors and ARBs: Ramipril, enalapril and losartan may have reduced blood-pressure-lowering effects, with increased risk of renal impairment.
  • Diuretics: Furosemide and hydrochlorothiazide may have reduced diuretic effectiveness and increased renal risks.
  • Lithium: COX-2 inhibitors may increase lithium concentrations and the risk of toxicity.
  • Methotrexate: Concurrent use may increase methotrexate exposure and toxicity, requiring appropriate monitoring.
  • Ciclosporin and Tacrolimus: Combined use may increase the risk of kidney damage.
  • Fluconazole: May increase celecoxib exposure through inhibition of CYP2C9 metabolism.

Frequently Asked Questions

The most frequently asked questions focus on import, export, documentations, and regulation for Etoricoxib.

The Etoricoxib is a pharmaceutical active pharmaceutical ingredient (API) used in manufacturing of Etoricoxib.

: Provides active pharmaceutical ingredients (APIs), customized production, and OEM/ODM services with research and technical cooperation across Europe, the USA, and India via Primeera Healthcare.

  • Therapeutic Goods Administration (TGA):
  • US Food and Drug Administration (USFDA):
  • European Medicines Agency (EMA):
  • African Medicines Agency (AMA):
  • National Medical Products Administration (NMPA):
  • Central Drugs Standard Control Organization (CDSCO):

Primeera Healthcare Private Limited can provide import coordination and pharmaceutical documentation assistance for Etoricoxib, subject to confirmation of its current regulatory status and eligibility for import into India.

Documentation Required for Etoricoxib Import

The import of medicines into India is regulated by the Central Drugs Standard Control Organisation (CDSCO) under the Drugs and Cosmetics Act, 1940, and the Drugs and Cosmetics Rules, 1945. The regulatory requirements depend on whether the product is an active pharmaceutical ingredient (API), a finished formulation, or an unapproved medicine intended for an individual patient's treatment.

Import Regulations and dcoumentation for Etoricoxib

  • Import Documentation Assistance:
    Support with organising commercial invoices, packing lists, manufacturer details, product specifications, certificates of analysis, and other relevant documents required for regulatory review and customs processing.

  • Regulatory Coordination:
    Assistance with identifying applicable CDSCO requirements, import authorisations, and documentation procedures, subject to the product's regulatory status and the proposed import route.
  • Shipping and Customs Coordination:
    Coordination with relevant logistics providers and customs professionals to organise shipment documentation and facilitate clearance where legally permitted.
  • Compliance Verification:
    Preliminary review of available product and shipment documentation to identify potential regulatory gaps before procurement or dispatch. Import arrangements will proceed only after the applicable permissions and restrictions have been verified.

Customs Clearance and Compliance Handling of Etoricoxib Import

Primeera Healthcare Private Limited can provide import coordination and pharmaceutical documentation assistance for Etoricoxib, subject to confirmation of its current regulatory status and eligibility for import into India.

Export Regulations and dcoumentation for Etoricoxib

The export of Etoricoxib from India is subject to applicable requirements under the Drugs and Cosmetics Act, 1940, the Drugs and Cosmetics Rules, 1945, and relevant export, customs, and destination-country regulations. Documentation requirements depend on whether the product is an active pharmaceutical ingredient (API), a finished pharmaceutical formulation, or a medicine intended for a specific market. Export eligibility and destination-country requirements must be verified before shipment.

Documentation Required for Etoricoxib Emport

  • Export Documentation Assistance:
    Assistance with organising commercial invoices, packing lists, manufacturer details, Etoricoxib specifications, certificates of analysis, and other supporting documents required for Etoricoxib export and customs processing.
  • Regulatory Coordination:
    Support in identifying applicable country specific Etoricoxib export requirements, relevant manufacturing and export authorisations, and destination-country registration or import approval requirements, subject to the Etoricoxib regulatory status.
  • Shipping and Customs Coordination:
    Coordination with logistics providers, freight forwarders, and customs professionals to organise shipping documentation, export declarations, and customs clearance procedures where legally permitted.
  • Compliance Verification:
    Preliminary review of available Etoricoxib documentation, labelling, Etoricoxib manufacturing information, and destination-market requirements to identify potential regulatory gaps before dispatch. Export arrangements will proceed only after the applicable restrictions and authorisations have been verified.

Customs Clearance and Compliance Handling of Etoricoxib Export

Primeera Healthcare Private Limited can provide pharmaceutical export documentation assistance, regulatory coordination, and shipping support for Etoricoxib, subject to confirmation of its export eligibility under applicable Indian regulations and the import requirements of the destination country.

Product Export Support

If you have any questions or need any help, contact our Support Team. We will get in touch with you within 24 hours from Monday to Friday between 9:00 and 10:00 CET.